Re: TG100801
Basically the same argument applies: how are you going to get a significant fraction of the drug across the eye? Consider that most of the drug in the eyedrop will rapidly drain out of the orbital socket via the drianage ducts.
I did notice that 801, the prodrug of 572 is a FAK inhibitor. Perhaps this is designed to increase scleral
permeability(?), but at the risk of what side effects? In general FAK (Focal Adhesion Kinase) is an important signaling molucule regulating the cytoskeletal structure of numerous cell types. 572 itself has multiple targets including VEGFR2, Src, and PDGFR. My gut instinct tells me that TG100572 on an intravitreal or subretinal implant could be effective, although the drug is dirty which means more worry about the risk of adverse side-effects on the retina itself, long-term. In any case, I suspect massive amounts of drug would have to be administered in eyedrop form to achieve a clear clinical benefit (IMHO).
Market Data 
Markets 
AI
